Chardan Capital reaffirmed their buy rating on shares of Gain Therapeutics (NASDAQ:GANX – Free Report) in a research report sent to investors on Friday morning, Benzinga reports. The firm currently has a $6.00 target price on the stock.
Several other research firms have also recently issued reports on GANX. HC Wainwright reaffirmed a buy rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research report on Thursday, July 11th. Oppenheimer reaffirmed an outperform rating and issued a $9.00 price objective on shares of Gain Therapeutics in a research report on Tuesday, April 23rd.
Check Out Our Latest Stock Report on Gain Therapeutics
Gain Therapeutics Stock Up 1.5 %
Gain Therapeutics (NASDAQ:GANX – Get Free Report) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.08. On average, equities analysts predict that Gain Therapeutics will post -1.03 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Gain Therapeutics
A number of institutional investors have recently bought and sold shares of GANX. Warberg Asset Management LLC purchased a new stake in Gain Therapeutics in the 2nd quarter worth $66,000. Renaissance Technologies LLC increased its stake in Gain Therapeutics by 154.2% in the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after buying an additional 72,000 shares in the last quarter. Finally, Hohimer Wealth Management LLC purchased a new stake in Gain Therapeutics in the 2nd quarter worth $422,000. 11.97% of the stock is owned by institutional investors.
Gain Therapeutics Company Profile
Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Featured Articles
- Five stocks we like better than Gain Therapeutics
- How is Compound Interest Calculated?
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- How to Invest in the Best Canadian Stocks
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- Upcoming IPO Stock Lockup Period, Explained
- MarketBeat Week in Review – 8/5 – 8/9
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.